Penn Medicine Co-Investment Program continues to thrive
Fiscal year 2022 saw the Co-Investment Program help launch and fund 2 new companies ViTToria Biotherapeutics and Dispatch Bio, as well as participate in follow-on rounds for Linnaeus Therapeutics, Car
Penn Spinout Regenxbio Opens New Gene Therapy Manufacturing Facility in Maryland
Regenxbio, a gene therapy company founded through collaboration with PCI, opened a new facility at its Maryland campus.
Five Years of Data Show Long-term Promise for Penn and Novartis’ Car-T Pioneer Kymriah
Five years after Penn and Novartis made history with the FDA approval of Kymriah, a recent study shows the long-term impact of the medication on patient remission rates.
Penn Partners with PaxeraHealth to Build AI Algorithms for Ultrasound Research
The collaboration between Penn and PaxeraHealth will concentrate on developing imaging algorithms to detect liver cancer in addition to covid detection via lung ultrasounds.
Penn to Use Covid-19 Vaccine Royalties to Fund Further Scientific and Medical Research
Covid-19 vaccine royalties from Karikó and Weissman's research are being re-invested into Penn’s research portfolio to support further discovery of life-saving therapies and technologies.
Philly Tech Week 2022: PCI and Pennovation Works Represent Penn with Robotics Showcase, Entrepreneur Expo and Future-Focused Conversation
Learn about the key highlights and events from the 12th Annual Philly Tech Week.
Tribeca Film Festival Documentary Features CAR-T Journey
Penn Medicine and Children’s Hospital of Philadelphia were in the spotlight at the Tribeca Film Festival in New York City, where the documentary “Of Medicine and Miracles" premiered.
Longfellow Real Estate to Develop New 455,000 Square Foot Life Sciences Facility at Pennovation Works
Read about Penn's latest expansion within the innovation ecosystem.
Penn Engineering Graduates Develop a Device to Reduce Ocean Microplastic Pollution
Read about how May graduates won the 2022 President's Sustainability Prize for their device that reduces microplastic pollution.
CAR-T startup Vittoria Biotherapeutics launches
Vittoria Biotherapeutics' mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies.